1. Roodman GD. Biology of osteoclast activation In cancer. J Clin Oncol 2001;19:3562-3571.

2. Sly WS, Whyte MP Sundaram V et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification N Engl J Med 1985;313:139-145.

3. Pfeilschifter J, Mundy GR. Modulation of transforming growth factor beta activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987;84:2024-2028.

4. Pawlicki M. Nowe taktyki leczenia przerzutów nowotworowych do kości. Współczesna Onkologia 2002;6:608-615.

5. Kolarz K, Treder M. Możliwości zaopatrywania ortopedycznego przerzutów nowotworów do kości. Współczesna Onkologia 2001;5:188-190.

6. Kaasa S, Brenne E, Lund JA, et al.: Prospective randomized multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol. 2006;79:278-284.

7. Bradley NM, Husted J, Sey MS, et al.: Review of patterns of practice and patients’ preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer. 2007;15:373-385.

8. Kälkner KM, Westlin JE, Strang P. 89 Strontium in the management of painful skeletal metastases. Anticancer Res. 2000;20:1109-1114.

9. Pons F, Herranz R, Garcia A, et al.: Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med. 1997;24:1210-1214.

10. Sciuto R, Tofani A, Festa A, et al.: Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med. 2000;41:647-654.

11. Lass P. Radioterapia izotopowa przerzutów nowotworowych do kośćca. Współczesna Onkologia 2001;5:185-187.

12. Shipman CM, Rogers MJ, Apperley JF, et al:. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
Br J Haematol. 1997;98:665-672.

13. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91:2004-2008

14. van der Pluijm G, Vloedgraven H, van Beek E, et al.: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98:698-705.

15. Pelger RC, Hamdy NA, Zwinderman AH, et al.: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998;22:403-407.

16. Laakso M, Lahtinen R, Virkkunen P, et al.: Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.Br J Haematol.1994;87:725-729.

17. Ross J.R., Saunders Y., Edmonds P.M., et al.: Systemic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ, 2003 327:469-475

18. Kanis JA, Powles T, Paterson AH, et al.: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone.1996;19:663-667.

19. Hillner B.E., Ingle J.N., Chlebowski R.T. et al.: American Society of Clinical Oncology 2003 update on the role of bishosphonate and bone health issues in women with breast cancer. J. Clin. Oncol., 2003; 21:

20. Berenson J.R., Hillner B.E., Kyle R.A. et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol., 2002; 17: 3719-3776